
C
Tier
Coenzyme central to energy metabolism and repair (not a peptide).
Longevity & Cellular Health
Coenzyme, not a peptide
WADA Status:
Not prohibited
Human Trial Scoreboard
Completed human RCTs
Precursors only, not IV
Largest Human Study
Size not verified
Longest exposure
Duration not verified
Most Recent Trial
Year not verified
Description
NAD+ is not a peptide and not a drug. It is a coenzyme present in every cell, essential to converting food into usable energy and to the function of several repair enzymes, and its levels decline with age. That decline is real and it is the basis for an entire supplement category. The important thing to understand is that four different products are sold under this banner and they are not equivalent. Taking NAD+ itself by mouth is largely futile because the molecule is broken down before absorption. The precursors, nicotinamide riboside and nicotinamide mononucleotide, are absorbed and have genuine trials behind them, though the results are more modest than the marketing. Intravenous NAD+, sold by wellness clinics, has the weakest evidence of the four and the highest price.
What Are The Claims
Claims made for this compound: Cellular energy; Recovery and focus support (claimed)
Evidence
Raising NAD+ is well demonstrated; producing a clinical anti-aging outcome in humans is not. IV administration adds infusion-related risk without adding outcome evidence.
Evidence Strength
Preliminary (precursor trials; IV NAD+ evidence thin)
Caveats
Safety
Alternative Measures
Legal Status
US
Dietary supplement (oral precursors); intravenous use not an approved treatment
UK
Supplement
EU
Supplement
AU
Supplement
WADA
Not prohibited
Not an approved drug. Injectable and IV NAD+ is offered through clinics and compounding in a contested regulatory space; oral precursors are sold as supplements.
Citations
No completed peer-reviewed human clinical trial exists for this compound. Where a citation is absent below, that absence is the finding.